Tüdőrák: nyitott vizsgálatok itt: Svédország
35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 2026. nov. 10.. Ask the study team whether a trial fits you.
3. fázisToborozTrial-stage medicine
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
- Where
- Solna
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06623422EU 2023-506327-29-00Regiszter frissítve: 2026-11-09
3. fázisToborozTrial-stage medicine
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
- Where
- Gavle, Goteborg, Umeå
- Age
- 18 év to 100 év
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT05920356EU 2022-501863-41-00Regiszter frissítve: 2026-11-06
1/2. fázisToborozTrial-stage medicine
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
- Where
- Goteborg
- Age
- 18 év and over
- People
- 320 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT05789082EU 2023-507171-22-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
- Where
- Eskilstuna, Gavle, Goteborg
- Age
- 18 év and over
- People
- 680 worldwide
- Run by
- Pfizer
See details and how to joinNCT07144280EU 2025-521281-97-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
- Where
- Gavle, Solna, Uppsala
- Age
- 18 év and over
- People
- 850 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361497EU 2025-523576-23-00Regiszter frissítve: 2026-11-05
3. fázisToborozTrial-stage medicine
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- Where
- Eskilstuna, Västerås
- Age
- 18 év and over
- People
- 1264 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06119581EU 2023-503412-33-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
- Where
- Lulea, Lund, Ostersund, Sundsvall, Umea
- Age
- 18 év and over
- People
- 444 worldwide
- Run by
- Bayer
See details and how to joinNCT06452277EU 2024-511319-91-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- Where
- Gothenburg
- Age
- 18 év and over
- People
- 700 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06890598EU 2024-512302-25-00Regiszter frissítve: 2026-11-04
3. fázisToborozTrial-stage medicine
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
- Where
- Goteborg, Solna
- Age
- 18 év and over
- People
- 400 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07195695EU 2025-521284-12-00Regiszter frissítve: 2026-11-02
2/3. fázisToborozTrial-stage medicine
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
- Where
- Gävle
- Age
- 18 év and over
- People
- 626 worldwide
- Run by
- Mirati Therapeutics Inc.
See details and how to joinNCT04613596EU 2023-508922-83-00Regiszter frissítve: 2026-10-30
3. fázisToborozTrial-stage medicine
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Where
- Goteborg, Solna
- Age
- 18 év and over
- People
- 768 worldwide
- Run by
- AbbVie
See details and how to joinNCT04928846EU 2023-505749-14-00Regiszter frissítve: 2026-10-29
1. fázisToborozTrial-stage medicine
Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)
- Where
- Solna
- Age
- 18 év and over
- People
- 554 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT04886804EU 2024-511246-39-00Regiszter frissítve: 2026-10-28
1/2. fázisToborozTrial-stage medicine
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
- Where
- Gothenburg, Stockholm
- Age
- 18 év and over
- People
- 450 worldwide
- Run by
- Bayer
See details and how to joinNCT06914128EU 2025-520623-24-00Regiszter frissítve: 2026-10-28
3. fázisToborozTrial-stage medicine
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
- Where
- Gavle, Goteborg, Solna
- Age
- 18 év and over
- People
- 670 worldwide
- Run by
- Boehringer Ingelheim
See details and how to joinNCT07472517EU 2025-520565-51-00Regiszter frissítve: 2026-10-28
2/3. fázisToborozTrial-stage medicine
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
- Where
- Goteborg
- Age
- 18 év and over
- People
- 590 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07063745EU 2025-521511-40-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
- Where
- Gavle, Solna
- Age
- 18 év and over
- People
- 750 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07361510EU 2025-523586-18-00Regiszter frissítve: 2026-10-23
3. fázisToborozTrial-stage medicine
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301]
- Where
- Stockholm
- Age
- 18 év and over
- People
- 420 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07099898EU 2025-521627-78-00Regiszter frissítve: 2026-10-20
1/2. fázisToborozTrial-stage medicine
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
- Where
- Lund, Stockholm
- Age
- 18 év to 130 év
- People
- 695 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT05417594EU 2023-504984-17-00Regiszter frissítve: 2026-10-05
2. fázisToborzás még nem indultResearch participation
A phase II randomised trial investigating the benefit of adjuvant immunotherapy after neoadjuvant chemoimmunotherapy for resectable NSCLC (ADIL)
- Where
- Gothenburg, Linkoping, Lund, Solna, Umeaa, Uppsala
- Age
- 18 év and over
- People
- 300 worldwide
- Run by
- Oslo Universitetssykehus HF
See details and how to join2025-524439-38-00EU 2025-524439-38-00Regiszter frissítve: 2026-09-28
No phaseToborzás még nem indultResearch participation
TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary Self-Sampling
- Where
- Stockholm
- Age
- 18 év and over
- People
- 40
- Run by
- Karolinska Institutet
See details and how to joinNCT07823725Regiszter frissítve: 2026-09-21
2. fázisToborozTrial-stage medicine
A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)
- Where
- Goteborg, Solna
- Age
- 18 év and over
- People
- 182 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06855771EU 2024-519814-29-00Regiszter frissítve: 2026-09-18
No phaseToborozResearch participation
Aspects of Quality of Life During Adjuvant Oncological Treatment for Locally Advanced Lung Cancer Which Include Immune Checkpoint Inhibitor.
- Where
- Gothenburg
- Age
- 18 év and over
- People
- 75
- Run by
- Göteborg University
See details and how to joinNCT07754409Regiszter frissítve: 2026-09-02
3. fázisToborzás még nem indultResearch participation
Does a higher radiation dose prolong survival of patients with limited-stage small cell lung cancer receiving immunotherapy after chemotherapy and radiation therapy (DAHRTS trial)?
- Where
- Gavle, Goteborg, Lund, Stockholm
- Age
- 18 év and over
- People
- 426 worldwide
- Run by
- Norges Teknisk-Naturvitenskapelige Universitet NTNU
See details and how to join2026-525513-31-00EU 2026-525513-31-00Regiszter frissítve: 2026-08-24
1. fázisToborozTrial-stage medicine
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
- Where
- Solna
- Age
- 18 év and over
- People
- 914 worldwide
- Run by
- Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840EU 2023-505858-18-00Regiszter frissítve: 2026-07-22
3. fázisToborozTrial-stage medicine
EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study
- Where
- Lund
- Age
- 18 év and over
- People
- 200
- Run by
- Region Skane
See details and how to joinNCT06486142Regiszter frissítve: 2026-05-14
Minden vizsgálat (Tüdőrák) és a térkép
Ez az oldal nem orvosi tanács. Mielőtt egy vizsgálatot megkeresel, beszélj az orvosoddal.